Provided is a composition for cancer diagnosis targeting a tumor and/or tumor microenvironment and a use thereof, and more specifically, a fluorescent contrast agent composition targeting biomolecules overexpressed in cancer cells and tumor microenvironment. According to the present disclosure, it is possible to provide a fluorescent contrast agent that may simultaneously target cancer (folate receptor alpha-expressing cancer) cells and tumor-associated macrophages in the tumor microenvironment.

Provided is a composition for cancer diagnosis targeting a tumor and/or tumor microenvironment and a use thereof, and more specifically, a fluorescent contrast agent composition targeting biomolecules overexpressed in cancer cells and tumor microenvironment. According to the present disclosure, it is possible to provide a fluorescent contrast agent that may simultaneously target cancer (folate receptor alpha-expressing cancer) cells and tumor-associated macrophages in the tumor microenvironment.

Provided herein are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Z.sup.1, Z.sup.2, Z.sup.3, R.sup.1, R.sup.2, R.sup.3, and n are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of using a compound of formula (I), or a pharmaceutically acceptable salt thereof, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

##STR00001##

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). ##STR00001## This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). ##STR00001## This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.